Dr. Barocas on Adjuvant Sunitinib in Renal Cell Carcinoma
Daniel A. Barocas, MD, MPH, FACS, discusses adjuvant TKI therapy in patients with renal cell carcinoma at high risk of recurrence following cytoreductive nephrectomy.